Asset & Portfolio Due Diligence

I provide strategic insight to investors, boards, and biopharma leaders evaluating assets or portfolios through a market access lens. My experience across global evidence and pricing enables me to identify the assumptions and risks that most affect value and commercial potential.

Whether you are exploring a single asset or an entire portfolio, I bring a disciplined yet pragmatic approach—focused on clarity, credibility, and what really drives payer and market adoption.

Alongside portfolio valuation and due diligence I also provide advisory support for boards and investors seeking a deeper understanding of access dynamics, payer expectations, and evidence-driven value creation. 

Key Deliverables